These test samples are processed using Biocept’s RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego.
“We are exceptionally proud to continue supporting our community with SARS-CoV-2 testing and providing healthcare providers with rapid turnaround of valuable information to help contain viral spread,” said Michael Nall, president and CEO of Biocept.
READ: Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing
“RT-PCR testing for COVID-19 currently remains an important component of our business while we focus on our core business, including the opportunity to serve patients diagnosed with advanced cancer through commercializing our differentiated CNSide neuro-oncology offerings,” Nall added.
To further strengthen its COVID-19 testing business, the company is moving ahead with plans to improve testing as a way to identify new variants of the SARS-CoV-2 virus, which causes the disease.
Biocept recently partnered with Aegea Biotechnologies Inc under a supply agreement for a new PCR-based coronavirus assay kit designed by Aegea and co-developed by both companies.
Aegea will supply the kit to Biocept for validation in its San Diego lab and the new assay will use Biocept’s patent-protected Switch-Blocker technology for viral RNA detection and discrimination of the L and S coronavirus strain types.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham